Product
C21
5 clinical trials
7 indications
Indication
COVID-19Indication
Idiopathic Pulmonary FibrosisIndication
Vasodilatory Effects of C21Indication
Raynaud's PhenomenonIndication
systemic sclerosisIndication
Type 2 diabetesIndication
Endothelial dysfunctionClinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 3, Multicenter Trial Investigating the Efficacy and Safety of C21 as add-on to Standard of Care in Adult Subjects With COVID-19Status: Completed, Estimated PCD: 2022-04-25
Clinical trial
A Phase 2, Multi-Centre, Open-Label, Single-Arm Trial Investigating the Safety, Efficacy and Pharmacokinetics of C21 in Subjects With Idiopathic Pulmonary FibrosisStatus: Completed, Estimated PCD: 2024-03-30
Clinical trial
A Phase 1, Open-label, Single-centre Study Investigating the Effect of C21 on Forearm Blood Flow in Healthy Male Subjects by Use of Strain-gauge Venous Occlusion PlethysmographyStatus: Completed, Estimated PCD: 2022-05-11
Clinical trial
A Phase 2, Single-center, Randomised, Double-blind, Placebo-controlled, Cross-over Cold Challenge Study Investigating the Effect of C21 on Cold-induced Vasoconstriction in Subjects With Raynaud's Phenomenon (RP) Secondary to Systemic Sclerosis (SSc)Status: Completed, Estimated PCD: 2020-12-14
Clinical trial
A Randomized, Double-blind, Placebo-controlled, 2-way Cross-over Trial Evaluating the Effect of C21 on Endothelial Dysfunction and Safety in Subjects With Type 2 Diabetes MellitusStatus: Completed, Estimated PCD: 2023-06-16